FOXC1 has been identified as a novel biomarker in addition to MKI67 and PD-L1 to measure the efficacy of immune checkpoint inhibitors (ICIs). Partha Ray, MD, Onconostic Technologies, Evanston, IL, describes the clinical applications of these findings. Whilst RNA sequencing techniques can evaluate patient responses, the technology may not be accessible to all clinicians. Immunohistochemistry assays incorporating the aforementioned biomarkers may be a viable solution. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.